|IUPAC name||endo-N-8- methyl-8- azabicyclo[3.2.1] oct-3-yl)- 2,3-dihydro-3- isopropyl-2-oxo- 1H-benzimidazol-1-carboxamide hydrochloride|
|ECHA InfoCard||Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).|
|Except where noted otherwise, data are given for|
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references
BIMU-8 is a novel compound which acts on an area of the brain stem known as the pre-Botzinger complex.
The pre-Botzinger complex has been found to drive respiration. BIMU-8 stimulates this area of the brain, causing an increase in the rate of respiration. BIMU-8 acts as a selective 5HT4 agonist and is one of the first compounds to be developed that was selective for this serotonin receptor subtype.
Practical use of BIMU-8
The most obvious practical use of BIMU-8 is to combine it with opiates in order to counteract the dangerous respiratory depressing properties of the latter. BIMU-8 does not affect the painkilling properties of opiates, which means that if combined with BIMU-8, large therapeutic doses of opiates could theoretically be given to humans without risking a decrease in breathing rate. Studies have shown BIMU-8 to be effective in rats at counteracting the respiratory depression caused by the potent opioid fentanyl, which has caused many accidental deaths in humans. However no human trials of BIMU-8 have yet been carried out.
Other studies have suggested a role for 5HT4 agonists in learning and memory, BIMU-8 was found to increase conditioned responses in mice, and so this drug might also be useful for improving memory in humans. Interestingly other selective 5HT4 agonists such as mosapride (the only 5HT4 agonist currently available for use in humans) have been found not to reduce respiratory depression, suggesting that BIMU-8 may affect 5HT4 receptors in a different way to other 5HT4 agonists, or alternatively that the anti-respiratory depressant effect of BIMU-8 is instead mediated through a different mechanism of action which has not yet been elucidated.
- Manzke T, Guenther U, Ponimaskin E, Haller M, Dutschmann M, Schwarzacher S, Richter D (2003). "5-HT4(a) receptors avert opioid-induced breathing depression without loss of analgesia". Science. 301 (5630): 226–9. PMID 12855812.
- Meneses A, Hong E (1997). "Effects of 5-HT4 receptor agonists and antagonists in learning". Pharmacol Biochem Behav. 56 (3): 347–51. PMID 9077568.
- Lotsch J, Skarke C, Schneider A, Hummel T, Geisslinger G. The 5-hydroxytryptamine 4 receptor agonist mosapride does not antagonize morphine-induced respiratory depression. Clinical Pharmacology and Therapeutics. 2005 Sep;78(3):278-87.